Bluetongue is a disease in ruminants caused by the bluetongue virus (BTV), and is spread by Culicoides biting midges. Bluetongue outbreaks cause huge economic losses and death in sheep in several parts of the world. The most effective measure to control BTV is vaccination. However, both commercially available vaccines and recently developed vaccine candidates have several shortcomings. Therefore, we generated and tested next-generation vaccines for bluetongue based on the backbone of a laboratory-adapted strain of BTV-1, avirulent BTV-6 or virulent BTV-8. All vaccine candidates were serotyped with VP2 of BTV-8 and did not express NS3/NS3a nonstructural proteins, due to induced deletions in the NS3/NS3a ORF. Sheep were vaccinated once with one of these vaccine candidates and were challenged with virulent BTV-8 3 weeks after vaccination. The NS3/NS3a knockout mutation caused complete avirulence for all three BTV backbones, including for virulent BTV-8, indicating that safety is associated with the NS3/NS3a knockout phenotype. Viraemia of vaccine virus was not detected using sensitive PCR diagnostics. Apparently, the vaccine viruses replicated only locally, which will minimize spread by the insect vector. In particular, the vaccine based on the BTV-6 backbone protected against disease and prevented viraemia of challenge virus, showing the efficacy of this vaccine candidate. The lack of NS3/NS3a expression potentially enables the differentiation of infected from vaccinated animals, which is important for monitoring virus spread in vaccinated livestock. The disabled infectious single-animal vaccine for bluetongue presented here is very promising and will be the subject of future studies.
INTRODUCTION
Bluetongue is an economically important disease in ruminants caused by the bluetongue virus (BTV). Symptoms of bluetongue can range from asymptomatic infection in cattle in enzootic regions to high mortality for certain European sheep breeds. The pathogenesis of bluetongue is caused mainly by damage to small blood vessels, causing fever, lameness, haemorrhage, ulcers in the oral cavity and upper gastrointestinal tract, muscle necrosis, coronitis, and oedema of the lungs and head (Maclachlan et al., 2009 ).
The BTV serogroup consists of at least 24 different serotypes showing a low level of cross-neutralization, and that form a complex structure of an inner (VP3), middle (VP7) and outer (VP2 and VP5) capsid layer. These layers encapsidate the viral polymerase (VP1) (Urakawa et al., 1989) , capping enzyme (VP4) (Sutton et al., 2007) and helicase (VP6) (Stäuber et al., 1997) , as well as the 10 genome segments (Roy, 2005) .
Bluetongue is a non-contagious, vector-borne disease, spread by Culicoides biting midges. The most effective measure to control bluetongue outbreaks is vaccination . Currently, live-attenuated and inactivated vaccines are marketed for a limited number of serotypes (reviewed by Niedbalski, 2011; Noad & Roy, 2009a; Roy et al., 2009) . Live-attenuated vaccines have been proven to be successful in controlling bluetongue outbreaks in several areas (Coetzee et al., 2012) . Their use is, however, controversial due to possible teratogenic effects, underattenuation, viraemia sufficient for onward vaccine virus transmission by vectors and the risk of virulent BTV variants by reversion to virulence or reassortment with field virus Ferrari et al., 2005; Savini et al., 2012; Veronesi et al., 2005) . Furthermore, use of these vaccines hampers monitoring of ongoing outbreaks by the lack of differentiation of infected from vaccinated animals (DIVA). Inactivated vaccines are safe regarding vaccine spread and are potential DIVA vaccines if purified from non-structural proteins (Anderson et al., 1993; Barros et al., 2009 ). However, both production costs and the antigen dose required for protection are high due to stringent downstream processing of antigen, i.e. virus purification, inactivation and formulation with adjuvant. Furthermore, prime-boost vaccination and annual boosting for each serotype are needed for full protection, which further increase the costs per protected animal.
A wide range of other vaccine candidates, such as subunits, vector vaccines, DNA vaccines, virus-like particles and a trans-complemented or disabled infectious single-cycle (DISC) vaccine, have been described (Anderson et al., 2013; Boone et al., 2007; Calvo-Pinilla et al., 2014; Huismans et al., 1987; Lobato et al., 1997; Matsuo et al., 2011; Roy et al., 1992; Thuenemann et al., 2013) . However, each of these alternatives has one or more shortcomings, such as low immunogenicity, low stability, high production costs, the need for a complementing cell line for production or lack of DIVA. Currently, there is no low-cost, safe, DIVA bluetongue vaccine available that induces lifelong protection against multiple serotypes. Due to the disadvantages of commercially available vaccines and the shortcomings of currently investigated vaccine candidates, a next-generation bluetongue vaccine is needed. The development of reverse genetics for BTV (Boyce et al., 2008; has made it possible to rationally design a bluetongue vaccine meeting the desired criteria.
NS3/NS3a proteins are involved in release of BTV (Celma & Roy, 2009 , 2011 Noad & Roy, 2009b; Wu et al., 1992) and suppress the induction of the IFN response (Chauveau et al., 2013) . It has been suggested that NS3/NS3a is involved in virulence for the related orbivirus, African horsesickness virus (Huismans et al., 2004; van Niekerk et al., 2001) . Recently, we showed that NS3/NS3a proteins are not essential for BTV replication in vitro by recovery of NS3/NS3a knockout BTV using reverse genetics (Feenstra et al., 2014; van Gennip et al., 2014) . The absence of NS3/ NS3a proteins results in a strongly reduced induction of cytopathogenic effect (CPE) in mammalian cells and reduced virus release from mammalian, but mainly insect cells. These findings suggest that NS3/NS3a knockout virus could be safe in vivo and may be a potential BTV vaccine candidate. We have also successfully exchanged outer-shell proteins VP2 (encoded by Seg-2) and VP5 (encoded by Seg-6) in vaccine-related BTV-6/net08 and showed that this virus was protective against virulent BTV-8 in vivo .
Here, we combined the NS3/NS3a knockout mutations and the exchange of Seg-2 of serotype 8 in three BTV backbones derived from virus strains that differed in virulence. Virulence as well as protective capacity of these NS3/ NS3a knockout BTV mutants were studied in sheep.
RESULTS
NS3/NS3a knockout BTV mutants with Seg-2 of serotype 8 are viable
Previously, we showed that expression of NS3/NS3a could be abolished in BTV-1 by partial deletions in the NS3/NS3a ORF of Seg-10 (Feenstra et al., 2014) . Here, we introduced deletion Seg-10 in cell-adapted BTV-1 as well as in vaccinerelated BTV-6 and virulent BTV-8. Mutated Seg-10 DD(S2del), DC and DDS2 lead to knockout of NS3/NS3a expression in BTV-1, -6 and -8, respectively (see Methods) (Feenstra et al., 2014) . These mutant segments were available at the time of the sheep trial and all led to complete knockout of NS3/NS3a expression, and were consequently phenotypically identical in this respect. In addition, VP2 (encoded by Seg-2) of serotype 8 was introduced successfully in the outer shell of BTV-1 and -6. This resulted in three different BTV backbones sharing the same serotype and the NS3/NS3a knockout phenotype, referred to as BTV-1 backbone, BTV-6 backbone and BTV-8 backbone. Indeed, the presence of Seg-2 from serotype 8 was confirmed by BTV-8 serotype-specific PCR, whereas serotype-specific PCR for serotype 1 was negative for all three viruses (Fig. 1a) .
Seg-10 of all viruses was completely amplified and separated by gel electrophoresis. Amplicons of the expected smaller size than full-length Seg-10 were visible for the BTV-6 and -8 backbones (Fig. 1a) . However, there were two Seg-10 amplicons detected for the BTV-1 backbone. Sequencing of both bands showed a duplication of 74 bp (position 40-113) of part of the DD(S2del) sequence at position 114 (not shown). This resulted in an additional larger Seg-10 amplicon, in accordance with Fig. 1(a) . As described previously by our group, such recombination events are common in Seg-10 deletion mutants, although this mutated Seg-10 was assumed to be genetically stable (Feenstra et al., 2014) . Still, all viruses were phenotypically stable and were not able to restore NS3/ NS3a expression.
BSR cell monolayers infected with NS3/NS3a knockout BTV mutants were not stained with different NS3 mAbs, whereas immunostaining with VP7-directed mAbs was positive. Lack of NS3/NS3a expression in all three BTV backbones was indeed confirmed by immunostaining. Immunostaining of BSR monolayers infected with WT BTV-1 was positive for both VP7-and NS3-directed mAbs (Fig. 1b) . No clear difference in virus growth was observed between the different BTV backbones. All showed delayed virus replication and a lower final virus titre compared with WT BTV-1 (Fig. 2a) . Furthermore, the different BTV backbones, all with the NS3/NS3a knockout mutation, showed no clear CPE compared with the morphology of WT BTV-1 and all three only formed small plaques, visualized by immunostaining with anti-VP7 mAb (Fig. 2b) .
Knockout of NS3/NS3a expression leads to avirulence and strongly reduced viraemia Groups of four sheep were vaccinated with a similar dose of BTV-1, -6 or -8 backbone, or with similar amounts of inactivated BTV-8. A fifth group served as the control group and received cell lysate. post-vaccination (d.p.v.) , only a very small increase in body temperature was measured in the BTV-8 backbone group (Fig. 3c) . On the contrary, after challenge of control sheep with virulent WT BTV-8, both fever and severe clinical signs were observed (Fig. 3 ). BTV-8 generated using reverse genetics has also been shown to be virulent in vivo in a previous experiment (van . Taken NS3/NS3a knockout BTV-6 with VP2 of serotype 8 protects against clinical signs and abolishes viraemia after challenge with virulent BTV-8
After BTV-8 challenge, none of the BTV-6-backbonevaccinated sheep showed fever. Two sheep in the BTV-8-backbone-vaccinated group showed fever (.40 u C) for 1 and 3 days. This seemed less severe and lasted a shorter time than in the control groups, and was not much more severe than in the BTV-6-backbone-vaccinated sheep. However, due to the low number of animals used, differences could not be shown to be significant.
All animals in the BTV-1-backbone-vaccinated group showed fever for at least 1 day [at 5 days post-challenge (d.p.c.)], which even lasted up to 4 days for one animal (from 4 to 7 d.p.c.). Both groups receiving inactivated BTV-8 or cell lysate developed fever for 3-4 days in the period from 5 to 11 d.p.c., except for one animal in the cell lysate group (Fig. 3c ).
Regarding clinical signs, two animals in the group vaccinated with the BTV-6 backbone developed very mild clinical signs late after BTV challenge at 11 d.p.c. In the group vaccinated with the BTV-8 backbone, two animals showed mild clinical signs earlier than in the BTV-6-backbone-vaccinated group. Five days after challenge, two animals in the group vaccinated with the BTV-1 backbone had difficulties with breathing. One day later, one animal in the group vaccinated with inactivated BTV-8 suffered from lesions in the oral cavity. From 7 d.p.c., several animals in all groups, except for the animals receiving the BTV-6 backbone vaccine, suffered from BTV symptoms, mainly breathing problems, facial oedema, red eyes ( Fig.  3b ) and lesions in the oral cavity. The severity of clinical signs (score up to 4 in one animal) and the number of affected animals (n53) in the group vaccinated with the BTV-1 backbone were remarkable (Fig. 3a) .
Viraemia post-virulent BTV-8 challenge was determined by RT-PCR testing of EDTA blood samples with both Seg-1 and Seg-10 panBTV PCR tests (Seg-10 PCR results not shown). At 3 d.p.c., all animals in all groups became PCRpositive, except for the BTV-6-backbone-vaccinated group and one sheep in the BTV-8-backbone-vaccinated group. Surprisingly, the BTV-6 backbone vaccination induced complete protection against viraemia, as virus replication of challenge virus could not be detected. Viraemia in the BTV-8-backbone-vaccinated animals post-challenge was significantly lower than in the groups vaccinated with the BTV-1 backbone, inactivated BTV-8 or cell lysate (P,0.05). One animal in this BTV-8 backbone group remained completely negative and none of the sheep showed C p values ,32. This indicated that vaccination with the BTV-8 backbone strongly reduced replication of challenge virus. One sheep in the BTV-1-backbone-vaccinated group was PCR-positive 1 day earlier than the control animals and viraemia was slightly lower; however, this difference was not significant (P.0.05). In the cell lysate control group, one sheep was PCR-positive at 1 d.p.c., negative at 2 d.p.c. and positive again at 3 d.p.c., and remained positive until the end of the experiment. All animals in the BTV-1 backbone, inactivated BTV-8 and cell lysate groups became positive with low C p values (Fig. 4a) .
NS3/NS3a knockout BTV mutants induce seroconversion for VP7 antibodies
The antibody-mediated immune response directed against VP7 was studied using a commercially available competition ELISA used for routine diagnostics for bluetongue. At 7 d.p.v., two out of the four sheep in each of the BTV-6 and -8 backbone groups were seropositive (.50 % blocking in the ELISA) for the first time, and in both groups all sheep were seropositive at 9 d.p.v. (Fig. 4b) . Up to challenge, these remained ELISA-positive, although two and one sheep showed a small decline in blocking percentage at 21 d.p.v. in the BTV-6 and -8 backbone groups, respectively. Seroconversion in the BTV-1-backbone-vaccinated group was slightly delayed. Two out of four animals were seropositive at 9 d.p.v. for the first time and a third sheep became positive at 11 d.p.v. One sheep remained seronegative, but showed blocking in the ELISA, with the highest value being 38 % at 9 d.p.v. Furthermore, the averaged ELISA signal declined faster than for the groups vaccinated with BTV-6 and -8 backbones, and was negative at 21 d.p.v./0 d.p.c. (Fig.  4b) . However, the ELISA signal for all backbone-vaccinated groups was significantly higher than in control groups (P,0.05). After challenge, ELISA signals rose more quickly in vaccinated groups than in the control groups, as would be expected by the boosting effect in vaccinated animals. Remarkably, the averaged ELISA signal after challenge of the BTV-6 backbone group was slightly lower than in all the other groups. Although not significant, this lower booster effect might be due to the absence of viraemia for challenge virus in this vaccinated group. NS3/NS3a knockout BTV-6 with VP2 of serotype 8 induces neutralizing antibodies (nAbs) against BTV-8
The induction and quantification of nAbs was examined by a serum neutralization test (SNT) using BTV-8 and sera collected at 0 d.p.v., 21 d.p.v./0 d.p.c. and 21 d.p.c. Titres of nAbs were expressed as the highest dilution of serum inhibiting CPE formation. At the start of the experiment, all animals were negative for serotype-8-specific nAbs. At 21 d.p.v./0 d.p.c., three out of four sheep of the BTV-6 backbone group showed nAbs titres for serotype 8 between 8 and 32. One animal each in the BTV-8 and -1 backbone groups had a low nAb titre of 4 and 2, respectively. At 21 d.p.c., all vaccinated and control sheep had high nAb titres (12-128) (Fig. 4c) .
DISCUSSION
Here, we present NS3/NS3a knockout bluetongue vaccine candidates that are avirulent and protect against virulent BTV challenge. NS3 antibody responses are induced after natural BTV infection, and NS3-based ELISAs are therefore appropriate tools for DIVA testing, as described previously in combination with inactivated bluetongue vaccines (Barros et al., 2009) . In addition to knockout of NS3/NS3a expression, VP2 of serotype 8 was introduced in the BTV backbones. Although VP5 could enhance the serotypespecific antibody response (Roy et al., 1990) , we only exchanged VP2 in the different BTV backbones. This implies that in future use in cocktail vaccines, vaccine viruses based on the same backbone differ only in VP2 and therefore cannot lead to new reassortants of vaccine viruses. Three vaccine candidates based on different BTV backbones were generated and their efficacy was tested in sheep. Candidates were based on cell-adapted BTV-1 (Boyce et al., 2008) , avirulent BTV-6/net08 (Maan et al., 2010) and virulent BTV-8/net07 . In a pilot experiment with two sheep, the BTV-1 strain, generated by reverse genetics (Boyce et al., 2008; seemed to be attenuated strongly (not shown). Virulent BTV-8 generated by reverse genetics, derived from BTV-8/net07 , was included to study the effect of the NS3/NS3a deletion in a virulent backbone. BTV-6/net08 was isolated in the Netherlands in 2008, but was not transmitted efficiently, and induced hardly any clinical signs after natural and experimental infection (Eschbaumer et al., 2010; . Full-genome sequencing has shown that BTV-6/net08 is closely related to liveattenuated BTV-6 vaccine virus (Maan et al., 2010) . BTV-6 generated by reverse genetics showed only mild clinical signs and an elevation of body temperature .
All vaccine candidates were avirulent, and the BTV-6 and -8 backbones induced protection against virulent BTV-8 in sheep. However, the BTV-1 backbone was clearly less protective than the BTV-6 and -8 backbones. Clinical signs in two out of four animals in this group had an earlier onset and were more severe compared with controls. However, as only four animals per group were used and BTV-induced clinical signs are highly variable, it cannot be concluded that the BTV-1 backbone enhances disease after virulent BTV infection. Further, enhancement of clinical disease after BTV vaccination is very unlikely and has never been described. The vaccine based on BTV-6 was highly protective as no viraemia could be detected after challenge, despite an accidently tenfold lower vaccine dose than for the other BTV backbones. Apparently, the vaccine based on BTV-6 is superior to those based on overattenuated BTV-1 and virulent BTV-8. In particular, the nAb response induced by the BTV-6 backbone was clearly higher compared with the other vaccine backbones. This may be due to better local replication, as very high C p values were detected in two of the four animals after vaccination. However, these results are not substantiated indications for this hypothesis and further research is needed.
The BTV-8 backbone did not induce fever and clinical signs in sheep. Similarly, the BTV-6 backbone was even less virulent than BTV-6 and did not increase body temperature . This shows that knockout of NS3/NS3a expression leads to complete attenuation of BTV.
NS3/NS3a knockout, serotyped bluetongue vaccine viruses do replicate in sheep. Although viraemia was hardly detectable by sensitive RT-PCR testing, the induced protection and seroconversion for all three vaccine candidates were much higher compared with injection using equal amounts of inactivated BTV-8. We assume that NS3/ NS3a knockout BTVs replicate only locally. This impaired virus replication in vivo is likely caused by the absence of NS3/NS3a, needed for virus release, which is in line with in vitro results (Fig. 2) . These findings show that the BTV backbones are promising vaccine candidates that do replicate in vivo, but probably do not induce viraemia sufficient for transmission by the insect vector. NS3/NS3a knockout BTVs can therefore be considered as disabled infectious single-animal (DISA) vaccines against bluetongue.
The protective dose of 261 ml 10 4 TCID 50 ml 21 for the BTV-6 backbone is very low compared with other replicating vaccines (Boone et al., 2007; Celma et al., 2013; Lobato et al., 1997; Matsuo et al., 2011) . However, the minimal protective dose has not yet been determined for many of these vaccine candidates, including the bluetongue DISA vaccine presented here. Bluetongue DISA vaccines can be produced on established and validated production cell lines. Although virus growth on BSR monolayers is delayed, we assume that production can be optimized.
Reassortment between live-attenuated vaccine and field virus is a serious concern in regard to viruses with a segmented genome, such as BTV Ferrari et al., 2005) . However, for the vaccine candidates presented here, exchange of mutated Seg-10 will result in avirulence of reassorted field virus, whereas unmutated Seg-10 in vaccine-related BTV-6 will remain avirulent (Eschbaumer et al., 2010; . Furthermore, exchange of Seg-2 and -6 encoding outer-shell proteins of virulent BTV-8 does not increase the virulence of BTV-6 (van Gennip et al., 2012a) . Finally, and most importantly, infection of the same mammalian or insect cell by both bluetongue DISA vaccine and field BTV at approximately the same time is necessary for reassortment, which is highly unlikely as bluetongue DISA vaccine does not circulate throughout the body of the vaccinated animal.
Bluetongue DISA vaccines do not express NS3/NS3a proteins, as confirmed by immunostaining with NS3-directed mAbs. Therefore, infected animals can be differentiated from vaccinated animals using an NS3 ELISA (Barros et al., 2009; Bougrine et al., 1998) . Recently described genetic DIVA is also possible by deletions in Seg-10 (van Rijn et al., 2013) , as PCR positivity after infection encompasses a much longer period than the infectious period (Di Gialleonardo et al., 2011; . The DIVA compliance is an important advantage of bluetongue DISA vaccines (Bhanuprakash et al., 2009; Roy et al., 2009 ).
DIVA, DISA and avirulence are genetically coupled on genome Seg-10 in the bluetongue DISA vaccines. Consequently, exchange of Seg-10 by reassortment will result in exchange of all advantageous properties of these vaccine candidates. A similar coupling of advantageous properties has been suggested for an experimental DISC vaccine based on in trans complementation of VP6 (Matsuo et al., 2011) . However, no reports on host seroresponses directed against VP6 have been published and VP6-based tests have not yet been developed. Furthermore, DISC vaccines still contain complemented VP6 protein during production and after virus purification, which potentially leads to false-positive results, in particular after revaccinations.
Here, protection was achieved at 3 weeks post-single vaccination. This protection is probably not serotype specific, as protection against virulent BTV-8 was also achieved at 3 weeks post-vaccination with BTV-6-based vaccines with exchanged outer-shell proteins of different serotypes, as has been shown previously . Further, the protective dose, duration of immunity and protection in other ruminant species are yet unknown and need further research.
In conclusion, VP2-serotyped, NS3/NS3a knockout BTV mutants are viable, avirulent, highly protective and potential DIVA vaccines that can be produced in standard production systems. This bluetongue vaccine platform will be explored for different serotypes by exchange of Seg-2 in one common bluetongue vaccine backbone, which provides the opportunity to combine these in multivalent vaccines. The development of this DISA vaccine for bluetongue will be continued.
METHODS
Cell culturing and viruses. BSR cells (a clone of BHK-21 cells; Sato et al., 1977) were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) containing 5 % FBS, 100 IU penicillin ml 21 , 100 mg streptomycin ml 21 and 2.5 mg amphotericin B ml
21
.
All virus stocks used for in vivo experiments were obtained by infection of BSR cells at low m.o.i. with harvesting of these cells when 100 % CPE was obtained or, in the absence of CPE, when .50 % of cells were immunostained using anti-VP7 mAb ATCC-CRL-1875 in a duplicate infection. Challenge virus BTV-8/net07 has been described previously and was isolated originally from a Holstein-Friesian cow NL441689187 from Bavel, the Netherlands (ISID ProMED-mail, 2007) on eggs and passaged three times on BHK-21 cells (BTV-8/net07/e1/bhkp3). Virus titres were determined by end-point dilution assays on BSR cells and expressed as TCID 50 ml
NS3/NS3a knockout mutants of BTV-1, -6 and -8 using reverse
genetics. Transfection experiments of BSR cells with T7-derived RNA transcripts from linearized plasmids were performed as described previously for BTV-1, -6 and -8 (van Gennip et al., 2012b) . Mutated Seg-10 DD(S2del), DC and DDS2 lead to complete and stable knockout of NS3/NS3a expression in BTV-1, -6 and -8, respectively (Feenstra et al., 2014) . DD(S2del) contains a deletion from bp 59 to 634 and has a 67 bp Seg-2 sequence inserted. DC contains a deletion from bp 102 to 263. DDS2 contains a deletion from bp 263-634 and has a 67 bp Seg-2 sequence inserted. In addition, Seg-2 originating from serotype 8 (van Gennip et al., 2012a) was introduced in BTV-1 and -6, resulting in BTV-1 backbone, BTV-6 backbone and BTV-8 backbone.
Characterization of NS3/NS3a knockout BTV mutants. The serotypes of Seg-2 and deletion Seg-10 were examined using PCR with serotype-specific primers , and Seg-10 primers F-full-S10* and R-full-S10 (Table 1) . First, viral RNA was isolated using the High Pure Viral RNA kit (Roche) according to the manufacturer's protocol. Entire BTV Seg-10 or parts of Seg-2 were reverse transcribed and amplified using the OneStep RT-PCR kit (Qiagen). Amplicons were separated on agarose gel by electrophoresis and isolated using the Zymoclean Gel DNA Recovery kit (Zymo Research) according to the manufacturer's protocol. The sequence of amplicons was determined using appropriate primers and the BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems) in an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems). The complete consensus sequence was assembled and determined using Lasergene SeqMan Pro software version 7.2.1 (DNASTAR).
To confirm the absence of NS3/NS3a expression of all three vaccine viruses, BSR cells were infected and immunostained according to standard procedures using NS3-specific mAbs (33H7, 32H2, 31E9 and 32B6) (Ingenasa), whereas infection was confirmed by immunostaining with VP7-specific mAb ATCC-CRL-1875. Body temperature and clinical signs were examined daily from 3 days before to 7 days after vaccination or challenge and every other day during the rest of the experiment (see Results). Clinical signs were scored according to the scoring table for BTV-8 animal trials (Table  S1 , available in the online Supplementary Material; van Gennip et al., 2012a). Statistical differences in body temperature were calculated using a split-plot ANOVA and maximal temperatures were compared using a pairwise t-test with P,0.05 indicating significance. Samples of serum and EDTA blood were collected at indicated days of the experiment (see Results).
RT-PCR testing. Samples of EDTA blood were examined for the presence of BTV by panBTV PCR tests targeting Seg-1 or -10. The Seg-1 PCR test detects all BTV serotypes, including the vaccine candidate backbones used here. The Seg-10 PCR would not detect the BTV-1 and -6 backbones due to mutations in the region of the reverse primer.
First, BTV RNA was isolated using the MagNApure 96 DNA and viral NA Small Volume kit (Roche) by the MagNA Pure isolation robot (Roche) according to the manufacturer's protocol . The real-time RT-PCR test for Seg-1 was performed using primer F-pan-S1, primer R-pan-S1 and probe P-pan-S1 (Toussaint et al., 2007) according to the all-in-one method, including the predenaturation step, as described for the panBTV Seg-10 test (van Rijn et al., 2012b) ( Table 1 ). The panBTV RT-PCR test for Seg-10 was performed using primer F-pan-S10, primer R-pan-S10 and probe Ppan-S10 as described previously (van Rijn et al., 2012b) ( Table 1) . C p values of each PCR were calculated. Samples without a calculated C p value but showing a visible increase of the OD 640/530 were interpreted as 40, whereas negative samples were set as 45. PCR results were interpreted as described previously . Statistical differences in C p values were calculated using a split-plot ANOVA and minimal C p values for each animal were compared using a pairwise ttest with P,0.05 indicating significance.
VP7 ELISA. The commercial Bluetongue Competition VP7 ELISA (ID.vet) was used to detect VP7 antibodies in serum samples according to the supplier's instructions. The percentage of blocking was displayed as 100 minus value. Significant differences were calculated using the ELISA plate reader read-outs in a split-plot ANOVA. Lowest read-outs of each animal between day 0 and 21 were compared between groups using a pairwise t-test, with P,0.05 indicating significance.
SNT. SNTs were performed with serum from sheep at 0, 21 and 42 d.p.v. according to Haig et al. (1956) . Briefly, samples of serum were inactivated for 30 min at 56 uC. An aliquot of 50 ml serum was added to 50 ml DMEM in a 96-well culture plate and diluted 1 : 1 seven subsequent times. An aliquot of 50 ml 100 TCID 50 of BTV-8/ net07/e1/bhkp3 virus was added to diluted sera and incubated for 1 h at 37 uC. Then, 2610 4 BSR cells in 100 ml were added to each well, incubated for 5 days at 37 uC and scored for CPE. All SNTs were performed in duplicate and the concentration of nAbs was determined by the highest serum dilution showing ,100 % CPE. 59-CCTCGGTAGTATCCCTCACG-39 F-full-S10* 59-GTTAAAAAGTGTCGCTGCC-39 R-full-S10 59-GTAAGTGTGTAGTGTCGCGCAC-39 F-pan-S1
59-TTAAAATGCAATGGTCGCAAT-39 R-pan-S1
59-TCCGGATCAAGTTCACTCC-39 P-pan-S1
59-6-FAM-CCGTGCAAGGTGC-MGB-39 F-pan-S10 59-AGTGTCGCTGCCATGCTATC-39 R-pan-S10 59-GCGTACGATGCGAATGCA-39 P-pan-S10 59-6-FAM-CGAACCTTTGGATCAGCCCGGA-XTAMRA-39
